DEV02660 Supplementary Material

Files in this Data Supplement:

• Supplemental Figure 1 -

  Fig. S1. Expression patterns of fgf8, raldh2 and cyp26a1 in wild type and cdx morphants. Expression of fgf8 (A-D), raldh2 (E-H) and cyp26a1 (I-L) in wild-type control embryos (A,E,I), cdx1a morphants (B,F,J), cdx4 morphants (C,G,K) and cdx1a/4 morphants (D,H,L) at the 80% epiboly stage. Scale bar in A: 100 μm for A-L.

• Supplemental Figure 2 -

  Fig. S2. Marker expression in embryos treated only with an inhibitor of Fgf or RA signalling. Expression of krox20 (A-D), hoxb1a (E-H), valentino (I-L), hoxb4a (M-P) and hoxb5a (Q-T) in fgf3/8 morphants (A,E,I,M,Q), SU5402-treated embryos (B,F,J,N,R), raldh2 morphants (C,G,K,O,S) and DEAB-treated embryos (D,H,L,P,T) at 22 hpf. Scale bar in A: 100 μm for A-T.

• Supplemental Figure 3 -

  Fig. S3. Inhibition of either the Fgf or RA signal did not perturb the others signaling gradient in cdx1a/4 morphant embryos. Expression of fgf3 (A) and fgf8 (B) in DEAB-treated cdx1a/4 morphants, and expression of raldh2 (C) and cyp26a1 (D) in SU5402-treated cdx1a/4 morphants, at 13 hpf. Scale bar in A: 100 μm for A-D.

• Supplemental Figure 4 -

  Fig. S4. Raldh2 is involved in the expression of hoxb5a. Expression of krox20 (A), hoxb1a (B), valentino (C), hoxb4a (D) and hoxb5a (E) in embryos that received injection of cdx1a/4MO and 4 ng raldh2MO. Scale bar in A: 100 μm for A-E.